Qingdao Haier Biomedical Co., Ltd. Class A
SSSE:68813931.59
CNY
-1.10
(-3.36%)
ISIN
CNE100003P25
Return %
Stock
S&P 500
1Y
-7.71
14.20
3Y
-9.95
81.12
5Y
-69.48
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhan Jie Liu
- Full Time Employees
- 2,945
- Sector
- Producer manufacturing
- Industry
- Industrial machinery
- Address
- Qingdao China
- IPO Date
- Oct 24, 2019
- Website
- haierbiomedical.com
- Similar Companies
- Business
- Qingdao Haier Biomedical Co., Ltd. is a China-based company primarily engaged in the research, development, manufacturing, and commercialization of biomedical low-temperature storage equipment and comprehensive Internet of Things (IoT)-driven digital solutions for the life sciences and healthcare sectors. Founded in 2005 and headquartered in Qingdao, Shandong Province, China, the company operates as a key member of Haier Group Corporation and is publicly listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The company operates across two core business segments, Life Sciences and Medical Innovation, offering an extensive portfolio of products and systematic solutions: biomedical cold storage and cryogenic equipment, including ultra-low temperature freezers, cryogenic storage systems, biomedical freezers, laboratory and pharmacy refrigerators, blood bank refrigerators, ice-lined refrigerators, solar direct drive (SDD) vaccine refrigerators, and liquid nitrogen storage systems; biosafety and general laboratory equipment, including Class II and Class III biological safety cabinets, clean benches, carbon dioxide incubators, centrifuges, autoclaves, freeze dryers, and laboratory water purification systems; IoT-integrated healthcare scenario solutions, including smart blood management networks connecting blood collection, cold chain transit, and clinical transfusion; smart vaccination solutions comprising automated vaccination clinics, mobile vaccination vehicles, and real-time cold chain monitoring networks; automated biobanking solutions featuring robotic cryogenic sample storage, intelligent retrieval, and RFID-enabled sample lifecycle management; intelligent hospital pharmacy management solutions, including automated drug dispensing systems and smart medicine cabinets; and laboratory consumables, including cryovials, pipette tips, cell culture consumables, and microplates. Qingdao Haier Biomedical Co., Ltd. caters to scientific research institutes, universities, biopharmaceutical enterprises, hospitals, disease prevention and control centers, blood stations, and public health agencies domestically and across more than 140 countries and regions worldwide, collaborating with international bodies such as UNICEF and the World Health Organization. In recent developments, the company has accelerated its strategic transition from a hardware manufacturer into a full-scenario life sciences and digital healthcare solution provider, expanding its offerings in automated bioprocessing, cell and gene therapy (CGT) equipment, and laboratory automation; deepened its presence in laboratory consumables and reagents through targeted capacity expansions and acquisitions; expanded its international localization strategy by establishing regional overseas subsidiaries, technical training centers, and direct logistics hubs across Europe, North America, and the Asia-Pacific; and launched new generations of green energy-saving refrigeration platforms utilizing frequency-conversion and hydrocarbon technologies, automated drug management systems, and AI-enabled digital biobank management platforms.